Fig 1.
Patient recruitment to cohort study.
Fig 2.
Serial serum concentrations of creatinine and cystatin C relative to AKI and hospital discharge status.
This figure represents the changes in absolute creatinine (a & b) and cystatin C (c & d) concentrations in each patients over 4 days following paraquat ingestion. Filled symbols represent patients who died in the hospital and the open symbols represent survivors. Patients were also grouped according to AKI severity; No-AKI (black triangle), AKIN1 (blue rhombus), AKIN2 (green square) and AKIN3 (red circles).
Table 1.
Baseline demographic and clinical profile.
Table 2.
Serum/urine levels of creatinine and cystatin C.
Fig 3.
Relative changes (%) in both creatinine and cystatin C.
Total of 37 severe patients included in this graph (non-survivors = 17 patients). In all the survivors, baseline was assumed as lowest concentrations during the hospital stay or at follow up (for both serum creatinine and serum cystatin C). Baseline serum creatinine level in non-survivors was estimated by solving MDRD formula for GFR of 75 ml/min.
Fig 4.
Relative changes (%) in both creatinine and cystatin C based different spectrum of baseline estimates.
Total of 37 severe patients included in this graph (non-survivors = 17 patients). In all the survivors, baseline was assumed as lowest concentrations during the hospital stay or at follow up. Baseline serum creatinine level in non-survivors was estimated by solving MDRD formula for GFR of 75 ml/min [black bolded line in the graph- serum creatinine (MDRD75)] or 0.9 mg/dl (75% of survivors had baseline levels below 0.9 mg/dl) (black dotted line- serum creatinine (75th centile). Similarly, baseline serum cystatin C in non-survivors was assumed as lowest values obtained (orange line) or estimated by solving cystatin C based CKD-EPI formulas (pink line) 21 for GFR of 75 ml/min [133 × (Cystatin C /0.8)−1.328 × 0.996Age (× 0.932 if female)].
Fig 5.
Daily GFR estimates in paraquat patients.
GFR was estimated based on serum cystatin C and creatinine and demonstrated a twofold higher GFR for estimation based on cystatin C estimates than creatinine.
Table 3.
Other kidney function indices profiles.
Fig 6.
Serial plasma paraquat concentration according to AKI severity and hospital discharge status.
This graph displays the predictability of deaths by current paraquat nomograms in this cohort. Filled symbols represent patients who died in the hospital and the open symbols represent survivors.
Fig 7.
Correlation and Bland-Altman plot for two different creatinine assay methods in two independent laboratories on same samples.
Excellent correlation was obtained between these two methods (a) Konelab (KL) Jaffe and Roche Hitachi (RH) Jaffe, (b) Konelab (KL) Jaffe and Konelab (KL) enzymatic and (c) Roche Hitachi (RH) Jaffe and Konelab (KL) enzymatic.